Abstract
The aim of this study was to investigate the histological changes following the treatment with abatacept compared with methotrexate (MTX) by an immunohistological examination of synovial tissue for eleven different molecules to detect the expression patterns of cytokines. We histologically assessed the synovial tissues from 10 methotrexate (MTX)-treated RA patients as controls and 5 abatacept plus MTX-treated RA patients. The synovium samples from both group were assessed by hematoxylin and eosin (HE) staining and analyzed for their expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), CD20, CD68, vascular endothelial growth factor (VEGF), CD4, CD8, CD28, CD80, and CD86 by an immunohistological examination. HE staining showed that there was a decrease in cell proliferation in the synovium of the RA patients who received abatacept compared with the controls. TNF-α, IL-6, and VEGF were not significantly different in either of the groups. On the other hand, MMP-3, CD68, CD4, CD8, CD20, CD80, and CD86 were significantly decreased in the abatacept group compared with the control (P < 0.05). Based on the histological analysis of the synovium, it appears that the efficacy of the treatment with abatacept may involve the inhibition of cell proliferation, with decreases in the expression of MMP-3, CD68, CD4, CD8, CD20, CD80, and CD86 in the synovium. These findings indicate inhibition of not only T cells but also B cells and macrophages, which likely plays a role in the efficacy of abatacept in RA patients.
References
Olsen NJ, Stein MC (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167–2179
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Beckr JC, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA-4Ig. N Engl J Med 349:1907–1915
Buch MH, Vital EM, Emery P (2008) Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 10:S5
Steinbrocker O, Traeger CH, Battman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662
van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920
Farahat MN, Yanni G, Poston R, Panayi GS (1993) Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rhem Dis 52:870–875
Cañete JD, Celis R, Hernández V, Pablos JL, Sanmartí R (2011) Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 69:935–936
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanbe, K., Chiba, J. & Nakamura, A. Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis. Rheumatol Int 33, 1883–1887 (2013). https://doi.org/10.1007/s00296-011-2326-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2326-8